Brightening Peptides: Melitane (Acetyl Hexapeptide-1) and Melanostatine-5 (Nonapeptide-1)
Two cosmetic peptides on the melanocortin pathway, studied at opposite ends of the same receptor. What Melitane and Melanostatine-5 actually are, the even-tone claim each can support, why they are not interchangeable, and how a formulator builds a brightening brief around them.
Published June 3, 2026 · 7 min read · By Pepoderma Regulatory Team
The brightening shelf is crowded with tyrosinase-targeting actives, but two cosmetic peptides approach the appearance of tone from a different and more upstream place: the melanocortin-1 receptor (MC1-R), the receptor where α-melanocyte-stimulating hormone (α-MSH) sets the melanin signal in motion. Melitane (Acetyl Hexapeptide-1) and Melanostatine-5 (Nonapeptide-1) are both studied around that receptor — but at opposite ends of it, which is exactly why they are not interchangeable. This guide separates the two for a formulator building a brightening or even-tone brief, with the claim each can safely support.
What is the difference between Melitane and Melanostatine-5?
Both are biomimetic cosmetic peptides studied around the MC1-R / α-MSH pathway, but in opposite directions. Melanostatine-5 (Nonapeptide-1) is studied as a proposed antagonist of α-MSH at MC1-R — it is studied as blocking the signal that would otherwise drive melanin synthesis, which is the basis for its even-tone and radiance narrative. Melitane (Acetyl Hexapeptide-1) is studied as a proposed α-MSH agonist at MC1-R, associated with melanogenesis-modulating and photoprotective behaviour. They sit on the same receptor pathway but are not substitutes, and a brief should choose deliberately rather than treat "MC1-R peptide" as one thing.
Identity reference
| Active | INCI name | CAS | Proposed MC1-R role |
|---|---|---|---|
| Melitane | Acetyl Hexapeptide-1 | 448944-47-6 | Studied as α-MSH agonist (melanogenesis-modulating / photoprotective) |
| Melanostatine-5 | Nonapeptide-1 | 158563-45-2 | Studied as α-MSH antagonist (even-tone / radiance) |
Both ship from Pepoderma with INCI name, CAS, and an allergen and trace-impurity sheet for CPNP and equivalent notifications. Both belong to the Brightening & Radiance category in the catalogue.
Melanostatine-5 (Nonapeptide-1) — the signal-blocker
Nonapeptide-1 is a nine-residue biomimetic peptide, sequence H-Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2, studied as a proposed competitive antagonist of α-MSH at MC1-R. The proposed idea is upstream of the pigment enzymes: rather than inhibiting tyrosinase directly the way many classic brighteners do, it is studied as blocking the receptor signal that would set the melanin cascade going in the first place. That places it squarely in the even-tone and radiance lane, and it is the family member most directly aligned with a "supports a brighter, more uniform-looking complexion" cosmetic story. The framing stays at the studied/proposed level — an even-tone cosmetic narrative, not a treatment for hyperpigmentation as a medical condition.
Melitane (Acetyl Hexapeptide-1) — the MC1-R modulator
Melitane is a biomimetic hexapeptide designed to reproduce a functional part of α-MSH, and it is studied as an agonist at MC1-R — the opposite receptor role to Melanostatine-5. The associated cosmetic narratives are melanogenesis modulation and photoprotective / soothing behaviour rather than simple lightening, which is why it is best positioned around radiance, even tone, and the appearance of a complexion better defended against environmental stress — and why its claim language deserves particular care. The honest formulator's framing is "an MC1-R-pathway peptide studied around melanin-pathway modulation and photoprotective support," kept firmly at the studied/proposed level, with no efficacy or medical promise attached.
Why they are not interchangeable — but can be layered
Because the two are studied at opposite ends of MC1-R, they are not drop-in substitutes for one another: one is studied as an agonist, the other as an antagonist. What a brand can do is build a layered even-tone claim that draws on both as a multi-vector story around the pathway, provided the claim language stays at the appearance level and does not assert a specific physiological outcome. For a brightening line that also wants a firmness or repair arm, either peptide pairs cleanly with a signal peptide such as Matrixyl or a carrier peptide such as GHK-Cu, since those address entirely different axes.
Formulation mechanics
Both are water-soluble peptides and behave alike on the bench:
- Add to the water phase cool and late on copper-clean process water.
- Hold a near-neutral pH window (roughly 5.5–7.0) with a buffer the rest of the stack tolerates.
- Both perform in anionic and non-ionic emulsions on polyglyceryl, lecithin, and sucrose-ester emulsifiers and slot into hydrogels.
- Pre-dissolve the powder in a small glycerin or propanediol slurry to keep it dispersing cleanly at higher loadings.
- Cosmetic peptides do not self-preserve — the preservation system has to hold the whole product.
Use level for both has a conventional cosmetic window, but the right loading depends on the carrier, the claim, and the price point; verify it against your own base. Our emulsion-stability guide covers the carrier work in detail.
Claim language that stays safe
This is the category where claim discipline matters most. The defensible framing is the appearance of even tone and radiance, the look of a more uniform complexion — never "whitening" as a medical outcome, never an efficacy percentage, never a claim to treat hyperpigmentation, melasma, or any clinical condition. Melitane in particular should not be described as a "brightener" in the lightening sense given its studied agonist role; frame it around MC1-R-pathway modulation and photoprotective support. Keep every mechanism at the studied/proposed level and make sure substantiation reduces to the specific INCI molecule on the label.
Talk to our regulatory team
Building a brightening or even-tone line?
Tell us the on-pack story and your base chemistry. Pepoderma will send INCI documentation, carrier and pH guidance, and samples for Melitane (Acetyl Hexapeptide-1) and Melanostatine-5 (Nonapeptide-1) — with claim-safe framing notes for each.
Frequently asked questions
- Are Melitane and Melanostatine-5 the same kind of brightening peptide?
- No — they are studied at opposite ends of the same receptor. Both are biomimetic peptides studied around the melanocortin-1 receptor (MC1-R) and the α-MSH pathway, but Melanostatine-5 (Nonapeptide-1, CAS 158563-45-2) is studied as a proposed antagonist of α-MSH (blocking the melanin signal), while Melitane (Acetyl Hexapeptide-1, CAS 448944-47-6) is studied as a proposed α-MSH agonist associated with melanogenesis modulation and photoprotective behaviour. They sit on the same pathway but are not substitutes, so a brief should choose deliberately.
- How does Melanostatine-5 (Nonapeptide-1) support an even-tone claim?
- Nonapeptide-1 is studied as a proposed competitive antagonist of α-MSH at MC1-R — studied as acting upstream of the pigment enzymes by blocking the receptor signal that would set the melanin cascade in motion, rather than inhibiting tyrosinase directly. That places it in the even-tone and radiance lane and makes it the family member most directly aligned with a 'supports a brighter, more uniform-looking complexion' story. The framing stays at the studied/proposed level — a cosmetic even-tone narrative, not a treatment for hyperpigmentation as a medical condition.
- Can Melitane and Melanostatine-5 be combined in one formula?
- They are not drop-in substitutes for each other because they are studied at opposite ends of MC1-R, but a brand can build a layered even-tone claim that draws on both as a multi-vector story around the pathway — provided the claim language stays at the appearance level. Both are water-soluble peptides added cool and late at a near-neutral pH (5.5–7.0), so they co-formulate in the same aqueous phase. Either also pairs cleanly with a signal peptide (Matrixyl) or carrier peptide (GHK-Cu) for a firmness or repair arm.
- How should brightening-peptide claims be worded to stay cosmetic?
- Keep everything at the appearance level: the look of even tone and radiance, the appearance of a more uniform complexion. Avoid 'whitening' as a medical outcome, avoid efficacy percentages, and never claim to treat hyperpigmentation, melasma, or any clinical condition. Melitane in particular should not be framed as a lightening 'brightener' given its studied agonist role — describe it around MC1-R-pathway modulation and photoprotective support. Every mechanism stays at the studied/proposed level, and substantiation must reduce to the INCI molecule on the label.